What's New in Esophageal Cancer

Moderator(s)

• 

  Melanie Edwards, MD (she/her/hers)

  Thoracic Surgeon
  Trinity Health Ann Arbor
  Ypsilanti, Michigan, United States

  Disclosure(s): Astra Zeneca: Advisory Board (Terminated)
• 

  Smita Sihag, MD, MPH (she/her/hers)

  Memorial Sloan Kettering Cancer Center
  New York, New York, United States

  Disclosure(s): No financial relationships to disclose

Presentations:

• 1:15 PM – 1:25 PM PT

  Interval Changes in Skeletal Muscle Index are Predictive of Overall Survival and Disease-Free Survival in Patients with Esophageal Cancer Undergoing Trimodality Therapy
  

  Uzair M. Jogiat, MD – University of Alberta
• 1:25 PM – 1:35 PM PT

  Food Deserts Increase Readmission Following Tri-Modality Therapy for Esophageal Cancer: A Multi-Institutional Study
  

  Joseph D. Phillips, MD – Dartmouth-Hitchcock Medical Center
• 1:35 PM – 1:45 PM PT

  Transcriptomic analysis of esophageal adenocarcinoma archived surgical samples with NanoString PanCancer panels reveals ANPEP/CD13 is associated with lymphovascular invasion and survival.
  

  Wayne Hofstetter, MD – MD Anderson Cancer Center - University of Texas
• 1:45 PM – 1:55 PM PT

  Immunotherapy - Evolving Role in Treating Esophageal Cancer
  

  Matthew Strickland, MD – Massachusetts General Hospital/Harvard Medical School
• 1:55 PM – 2:15 PM PT

  Expert Panel—Esophageal Cancer Surgery in the Immunotherapy Era
  

  Daniela Molena, MD – Memorial Sloan Kettering Cancer Center

  Matthew Strickland, MD – Massachusetts General Hospital/Harvard Medical School

  Rishindra M. Reddy, MD, MBA (he/him/his) – University of Michigan